1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1177/0897190008322290" target="_blank" rel="noreferrer noopener">http://doi.org/10.1177/0897190008322290</a>
Pages
65–74
Issue
1
Volume
22
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Recent developments in the treatment of rheumatoid arthritis.
Publisher
An entity responsible for making the resource available
Journal of pharmacy practice
Date
A point or period of time associated with an event in the lifecycle of the resource
2009
2009-02
Subject
The topic of the resource
Antibodies; Arthritis; Immunosuppressive Agents; Rheumatoid; Rheumatoid – Complications; Monoclonal – Administration and Dosage; Antirheumatic Agents – Administration and Dosage; Biological Response Modifiers – Administration and Dosage; Rheumatoid – Drug Therapy; Rheumatoid – Epidemiology; Rheumatoid – Physiopathology
Creator
An entity primarily responsible for making the resource
Bruce SP
Description
An account of the resource
The introduction of biologic response modifiers has revolutionized treatment approaches in rheumatoid arthritis. The ideal treatment approach to induce remission and minimize joint destruction is yet to be determined, however. The guidelines for the treatment of rheumatoid arthritis were updated in 2008. Evidence published recently may help to guide treatment decisions. In this review, advances in treatment approaches are discussed with added emphasis on the cardiovascular risks to this patient population. New data regarding the biologic response modifiers currently available in the US, abatacept and rituximab, are reviewed. Finally, emerging therapies are introduced, including tocilizumab. Investigational agents in development may provide additional options in the future treatment of rheumatoid arthritis.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1177/0897190008322290" target="_blank" rel="noreferrer noopener">10.1177/0897190008322290</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2009
Antibodies
Antirheumatic Agents – Administration and Dosage
Arthritis
Biological Response Modifiers – Administration and Dosage
Bruce SP
Department of Pharmaceutical Sciences
Department of Pharmacy Practice
Immunosuppressive Agents
Journal of pharmacy practice
Monoclonal – Administration and Dosage
NEOMED College of Pharmacy
rheumatoid
Rheumatoid – Complications
Rheumatoid – Drug Therapy
Rheumatoid – Epidemiology
Rheumatoid – Physiopathology